Jazz Pharmaceuticals Improvement Grants:

Improving Guideline-Concordant Glioma Molecular Testing and Treatment in the United States

Request for Proposals

Last Updated: September 4, 2026

Applications Due: October 15, 2026

Link to Funding Opportunity

Application Portal: everygrant.smapply.us

Quality Improvement Initiative: Improving Guideline-Concordant Glioma Molecular Testing and Treatment in the United States

Purpose

Gliomas are a heterogenous group of central nervous system (CNS) tumors originating from glial or glial precursor cells and account for the majority of malignant primary CNS tumors. The 2021 Fifth Edition of the Classification of CNS Tumors restructured glioma diagnosis around molecular features that are now required for accurate diagnosis, grading, and prognostication[1]. The National Comprehensive Cancer Network (NCCN) has incorporated the WHO classification into both the Adult and Pediatric CNS Cancers Guidelines[2,3]. As result, integration of molecular testing into routine glioma diagnosis is critical to the determination of patient eligibility for guideline-concordant standard of care, inclusive of targeted therapy and clinical trials[4]. However, despite clear guidelines, gaps remain in the real-world utilization of the molecular classification of gliomas in the United States, especially in community oncology settings[5].

To address this gap, Conquer Cancer, the ASCO Foundation and Jazz Pharmaceuticals are collaborating to offer a Quality Improvement funding opportunity for projects that will develop and deliver strategies to improve guideline concordant testing and care to glioma patients. Projects should be designed to provide meaningful impact for patients and be sustainable and transferable to other settings.

With the goal of this program to improve care for glioma patients, applicants are encouraged to include the perspective of patients. This could include (but not limited to) collaborating with patient advocates, advocacy groups, or other organizations representing the patients would be impacted by this work.

Organization Information

This grant program is a collaboration between Jazz Pharmaceuticals and EveryGrant® powered by Conquer Cancer, designed expressly to meet the needs of glioma patients and care providers. Conquer Cancer acts as the primary administrator for the review and evaluation of applications. Grant funding will be provided directly to recipients by Jazz Pharmaceuticals.

Background

Managing and treating glioma remains a significant challenge in oncology care. Despite advances of care over decades of research, the median overall survival for patients with aggressive gliomas remains 12-16

---

[1] Louis DN, Perry A, Wesseling P, et al. Neuro-Oncol. 2021;23(8):1231-1251
[2] NCCN. Clinical Practice Guidelines in Oncology. Pediatric Central Nervous System Cancers. Version 1.2026. National Comprehensive Cancer Network. Accessed August 6, 2026.
[3] NCCN. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 2.2026. National Comprehensive Cancer Network. Accessed August 6, 2026
[4] Horbinski C, Solomon DA, Lukas RV, et al. JAMA Oncol. 2025;11(3):317-328
[5] Society for Neuro-Oncology, Community Neuro-Oncology Committee - Group Biomarker Letter V2.12.2025

months[6]. One significant issue is the underutilization of molecular testing and subsequent biomarker driven treatments. In particular, there is gap the real-world utilization of the molecular testing and classification of gliomas in the United States, especially in community oncology settings[7,8]. There are several factors that may contribute to this under-utilization, including resource limitations, lack of reflex testing, and longer turnaround times in community oncology settings.

The Society of Neuro-Oncology (SNO) Community Neuro-Oncology Committee has recognized this issue and recommends that any barriers preventing standard of care testing should be addressed and corrected to avoid unnecessary negative impact on patients[9]. The goal of this program is to address these gaps in glioma care and ensure that adult and pediatric patients receive -concordant molecular testing and timely treatment that is guideline-concordant. Nothing in this RFP is intended to direct or influence independent clinical decision-making. Treatment decisions remain the responsibility of treating healthcare professionals and their patients

RFP Detail and Eligibility

RFP Intent and Scope	• The intent of this RFP is to request proposals for the implementation of strategies that will support and measurably improve equitable delivery of guideline concordant molecular testing and care for pediatric and adult glioma in the United States. • Proposals should describe the application of quality improvement standards to evaluate current adherence to treatment guidelines, evaluation of guideline-discordant care and measures to improve guideline-concordant testing and care for patients with glioma. • Proposals should address equitable access to care and involve all stakeholders, including the patient community where appropriate. • Proposals should be designed to be sustainable, scalable, and transferable. • Proposed projects should be executed with the intent to disseminate the process and outcomes of the project with the broad oncology community involved in delivering care to this patient population. • Projects that improve knowledge of and access to precision medicine and improve testing efficiency in the community setting are strongly encouraged.
Eligibility	Geographic Scope: USA Applicant Eligibility Criteria: • The following may apply:

[6] Guishard AF, Yakisich JS, Azad N, Iyer AKV. J Clin Neurosci. 2018 Jan;47:28-42.
[7] Corey Neff et al., Neuro-Oncology Practice 10, no. 1 (2023): 24–33
[8] Porter AB, Wen PY, Polley MC. Am Soc Clin Oncol Educ Book. 2023;43:e389322
[9] [9] Society for Neuro-Oncology. Group Biomarker Letter. Society for Neuro-Oncology website. Published December 2025. Accessed August 5, 2026

	○ US healthcare delivery systems, academic and community oncology delivery networks ○ Applications from community cancer care providers are encouraged. • Proposals should represent multi-disciplinary teams delivering care to glioma patients. • Collaboration among healthcare centers and organizations, especially community care providers, is encouraged to foster interactive sharing of knowledge and expertise • Proposals that include collaboration with patient advocates, advocacy organizations, of other groups that can represent the perspective of glioma patients, are encouraged. • Awards will be made only to eligible organizations and institutions. Individual healthcare professionals are not eligible to receive awards directly
Requirements	
Date RFP Issued	1 September 2026
Clinical Area	Neuro-Oncology/Oncology: Adult and Pediatric Glioma
Area of Interest	Topics of Interest Include but are not limited to: • Strategies to ensure implementation of guideline concordant molecular testing and care for patients with glioma • Equitable access to precision medicine for glioma patients, particularly in the community setting. • Projects aimed at improving collaboration of glioma care and local/regional referral pathways across centers of excellence and community practices. • Use of clinical data to identify and address gaps in guideline-concordant testing and care for glioma patients. This may include (but is not limited to) treatment data, testing patterns and timelines, and prescription/care patterns. • Establishing and enhancing multi-disciplinary teams to ensure glioma patients receive appropriate guideline-concordant testing, treatment, and management • It is expected that projects will be evidence-based with planned evaluation of the impact of interventions that follow generally accepted scientific principles and are of the caliber to be presented at scientific meetings and published. • All proposals should include evidence of challenges present in the care delivery system and involve the patient population impacted as well as the cross functional care delivery team responsible for treatment. • All proposals should be designed to be sustainable beyond the grant funding period and be scalable to broader application following the project. • It is not the intention of the grant to fund the creation of roles in care delivery. • It is not our intent to support clinical research projects. Projects evaluating the efficacy/safety of therapeutic or diagnostic agents will not be considered

Target Audience	• Key stakeholders in glioma care including but not limited to neuro-oncologists, medical oncologists, pathologists, radiation oncologists, radiologists, neurosurgeons, and allied healthcare providers
Expected Approximate Monetary Range of Grant Applications	The total available budget for this RFP is $1,000,000 USD Individual projects requesting up to $125,000 USD will be considered The amount of the grant that the panel is prepared to fund for any project will depend upon the joint review panel's evaluation of the proposal and costs involved and will be stated clearly in the grant agreement
Key Dates	• RFP Release Date: 1 September 2026 • Full Proposal Date: 15 October 2026 • Review of Full Proposals by Review Panel: 15 November2026 • Anticipated full proposal notification date: end of November 2026 • Grants will be distributed following a fully executed agreement • Anticipated Project State and End Dates: January 2027 to December 2028
How to Submit	All applications must be submitted in accordance with the requirements and instructions of this Request for Proposals (RFP). All application materials must be in English and must be submitted online through the EveryGrant application portal. Please note, applicants will be prompted to create an account prior to submitting an application. No paper applications sent by mail, e-mail, or fax will be accepted.
Review Process	Jazz and Conquer Cancer, in collaboration with the SNO, will convene a Scientific Review Committee that will serve as the Expert Review Panel (ERP). The ERP will be composed of subject matter experts who will perform an independent and confidential peer review of all in-scope proposals. Jazz Pharmaceuticals will participate as a non-voting member of the ERP. The ERP's collective recommendations will define which proposals are awarded funding. Jazz Pharmaceuticals will allocate funds upon ERP recommendations. Reviews will be based on the following criteria: • Impact and innovation of the proposed project • Approach and feasibility • Scalability, transferability, and sustainability • Organizational capacity and leadership • Adherence to the requirements set forth in this RFP
Full Application Instructions	
Eligibility Form	Applicants must complete the eligibility form to confirm they align with the criteria noted in this RFP. In addition, please confirm the program you are applying for. For this RFP, please select "**Improving Guideline-Concordant Glioma Molecular Testing and Treatment in the United States.**"
Applicant Information	Please enter the information requested for the Principal Investigator of the project and upload a copy of the PI's NIH Biosketch or Science Experts Curriculum Vitae (SciENcv).

Project Information	Please enter your project title and summary/abstract where prompted. If the project will require an IRB, please provide the IRB approval status, assurance number, and approval/expiration dates.
Quality Improvement Proposal	Please upload a PDF file of your proposal with the following sections. Proposals must not exceed **10 pages.** There is no minimum page requirement.
Goals and Objectives	Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s). List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project
Assessment of Need for the Project	Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information
Target Audience	Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods	Describe the planned project and the way it addresses the established need. If your methods include educational activities, please describe succinctly the topic(s) and format of those activities
Evaluation and Outcomes	In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data. Quantify the amount of change expected from this project in terms of your target audience. Describe how the project outcomes will be broadly disseminated
Anticipated Project Timelines	Provide an anticipated timeline for your project including project start/end dates
Organization Detail	Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.
Description of QI Experience	Please provide a **one-page** summary of the PI or project teams prior relevant quality improvement experience.
Budget Detail	Please use the budget form provided in the online portal. All requested amounts must be in U.S. dollars (USD). When developing your budget please adhere to the following guidelines:

	• Indirect costs may be included in the requested budget, but are subject to approval by Jazz if selected. • Budget Cap: Total costs – including overhead – must not exceed the maximum budget limit of $125,000 over a 24-month period.
Institutional Letter of Support	Please upload an institutional letter of support confirming your organization's commitment to the project and any allocated resources and confirmation of the PI's current position within the organization.
Collaboration Letters (optional)	Please upload letters from any collaborating organizations or investigators to support your project.
Additional Information (optional)	If there is any additional information you feel the ERP should be aware of concerning the importance of this project, please upload it here.
Applicant Organization Information	Principal Investigators must complete all applicant organization details within the online portal. **This section is required for funding consideration; incomplete applications will be administratively disqualified.** Please provide the following: • Organization Details: Legal name and full address • Organizational Classification: For-profit or nonprofit status • Tax ID: Employer Identification Number (EIN) • Authorized Signing Official Signature Page: Uploaded using the provided template

About Jazz Pharmaceuticals

Jazz Pharmaceuticals' purpose is to innovate to transform the lives of patients and their families.

Jazz is dedicated to developing life-changing medicines for people with rare diseases — often with limited or no therapeutic options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what's possible – to make the "small wins" big again.

Jazz has a diverse portfolio of marketed medicines including leading therapies addressing rare epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics.

About Conquer Cancer, the ASCO Foundation

Conquer Cancer®, the ASCO Foundation, funds research for every cancer, every patient, everywhere. Since 1984, its Grants & Awards program has awarded more than $215 million through more than 10,500 grants and awards to improve cancer care and accelerate breakthroughs in clinical and translational oncology research. For more information visit CONQUER.ORG.

Powered by Conquer Cancer, EveryGrant® is a comprehensive grant management service that blends decades of grantmaking success with a global network of experts to help organizations design innovative funding programs—all without navigating the complexities of building them in-house. Contact us at EveryGrant@conquer.org.